Skip to content
DataLookout
Menu

NCT06340451

Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 22 versions: 22 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 24 words Show 4 more changesShow less
    • Trial completed
    • Enrollment target: estimated 132 to confirmed 133
    • Primary and study completion dates changed from estimate of Oct 2026 to Sep 30, 2026
    • Site details revised at 3 of 18 sites
  2. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Primary and study completion pushed from Aug 2026 to Oct 2026
    • Site details revised at 18 of 18 sites
    v21
  3. Minor Primary and study completion pushed from Mar 2026 to Aug 2026v20
  4. Notable Phase: Phase 3 to Not applicable
    • Start date: Apr 16, 2024 to Jul 11, 2024
    • Site details revised at 11 of 18 sites
    v19
  5. Notable Primary and study completion dates: Apr 2025 to Mar 2026
    • Study sites: 17 to 18
    v18
Show 16 earlier versionsHide 16 earlier versions
  1. Minor Study sites: 16 to 17v17
  2. Minor Study sites: 15 to 16v16
  3. Minor Study sites: 13 to 15v15
  4. Minor Study sites: 12 to 13v14
  5. Minor Study sites: 11 to 12v13
  6. Minor Study sites: 10 to 11v12
  7. Minor Study sites: 9 to 10v11
  8. Minor Study sites: 8 to 9v10
  9. Minor Study sites: 7 to 8v9
  10. Minor Study sites: 6 to 7v8
  11. Minor Study sites: 5 to 6v7
  12. Minor Study sites: 4 to 5v6
  13. Minor Study sites: 3 to 4v5
  14. Minor Study sites: 1 to 3v4
  15. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2024 to Apr 16, 2024
    v3
  16. Notable Primary endpoint revisedv2 Show 4 more changesShow less
    • Eligibility criteria expanded, about 4 words
    • Start date: Mar 2024 to Apr 2024
    • Secondary endpoints revised (4)
    • Study description expanded, about 3 words
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from baseline in the Modified Ashworth Scale score for elbow measured (0 to 4, where lower scores represent normal muscle tone and higher scores represent spasticity)
Timeframe: at week 13

Secondary (4)

Change from baseline in the Modified Ashworth Scale) score for shoulder (shoulder abduction) measured
Change from baseline in the Modified Tardieu Scales for elbow (0 to 5, where lower score represents no resistance, and higher score represents joint immobility; Increase in angle from baseline [R1, and R2] represents improvement)
Change from baseline in the Modified Tardieu Scales for shoulder (shoulder abduction)
Change from baseline in Goal Attainment Scale score evaluated by the blinded, trained, licensed medical staff (-2 to +2, where lower score represents less expected outcomes, and higher scores represent greater expected outcomes)

Arms and interventions

iovera° system treatmentActive comparator
sham iovera° system treatmentSham comparator

Devices: iovera° system, sham iovera° system treatment

Sites

18 sites in 1 country